Cybin has unveiled phase 2 results with its psychedelic medicine for major depressive disorder, which it says support moving the drug into a phase 3 programme.
People with depression can sometimes have impaired memory, particularly for positive events, which can contribute to cognitive problems and impair their daily lives.
Japanese pharma group Otsuka has signed an agreement to acquire Canada's Mindset Pharma, a specialist in psychedelic medicines for neuropsychiatric disorders.
Juli, an artificial intelligence-powered platform to help people manage chronic health conditions, has been shown to improve outcomes in a pair of randomised clinical tria
In another example of consolidation in the digital therapeutics (DTx) category, Big Health has agreed to buy Limbix, adding its app for adolescents and young adults with s
Psilocybin, a psychedelic compound found in certain mushrooms, could offer a more cost-effective treatment option for major depressive disorder than current methods, according to rese
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company